Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both... Both drugs are being developed by Sarawak Pharmaceuticals.
- Mechanism
- Curator reviewed
Viral life-cycle studies indicate that calanolide A acts early in the infection process, similar to the known HIV reverse transcriptase (RT) inhibitor 2', 3'-dideoxycytidine. In enzyme inhibition assays, calanolide A potently and selectively inhibits recombinant HIV type 1 RT but not cellular DNA polymerases or HIV type 2 RT within the concentration range tested.
- Primary indication
- For use in combination treatment of HIV infection (AIDS).Curator reviewed
- Formula / weight
- C22H26O5 · 370.4388 g/mol (avg)
Resolves to
NIDRYBLTWYFCFV-FMTVUPSXSA-NSMILESCCCC1=CC(=O)OC2=C1C1=C(C=CC(C)(C)O1)C1=C2[C@@H](O)[C@H](C)[C@@H](C)O1What you can answer from here — as of April 02, 2025
Which drugs share a target with Calanolide A, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account